Imagine a tumor as a fortress with its own supply lines. Instead of attacking the fortress walls, this therapy cuts off the roads and water pipes that feed the tumor. It also sends a signal to the body's own security guards to come and clear out the area. This dual attack aims to starve the cancer and let the immune system finish the job.
Patients with platinum-resistant ovarian cancer have limited treatment options because tumors often develop resistance to standard therapies and are highly heterogeneous.
A Phase 3 clinical trial (OVAL study) and a Clinical Study Report for the gene therapy candidate VB-111.
If you are a drug developer dealing with tumors that resist standard chemotherapy — this project developed VB-111, a gene therapy that targets the tumor microenvironment rather than the cells themselves to overcome resistance.
If you are a CRO dealing with large-scale international trials — this project managed a Phase 3 study involving 409 enrolled patients across 86 clinical sites in the US, Israel, Spain, Poland, and Japan.
If you are a clinic dealing with platinum-resistant ovarian cancer patients — this project tested a targeted anti-cancer gene therapy designed to recruit the immune system into the tumor.
Based on available project data, the specific price of the VB-111 treatment is not mentioned; however, the EU contribution for this project was EUR 2,500,000.
The therapy reached a late-stage clinical scale, with a Phase 3 trial involving 409 enrolled patients across 86 international sites.
Based on available project data, the therapy VB-111 is the lead product candidate of Vascular Biogenics Ltd, but specific licensing terms are not provided.
The trial was terminated early following a recommendation from the iDSMC because the primary analysis for progression-free survival (PFS) and interim overall survival (OS) were not met.
Recruitment for the OVAL trial took place between December 2017 and March 2022.
The project was managed by a single partner, Vascular Biogenics Ltd, an SME based in Israel. This 100% industry-led consortium indicates a focused, company-driven effort to move a proprietary product (VB-111) through the final stages of clinical registration.
Contact Vascular Biogenics Ltd regarding the VB-111 gene therapy platform.
Analyze similar gene therapy failures to optimize future oncology trial designs.
